Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.

Ulagamadesan VenkatesanRajibul MianChinthanie RamasundarahettigeKelley R H BranchStephano Del Prato Carolyn Su Ping LamRenato D LopesRichard PratleyJulio Rosenstock Naveed Sattar

Published in: Diabetes, obesity & metabolism (2023)

In high-risk people with diabetes, eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of kidney-related risk category.

Keyphrases

cardiovascular disease
small cell lung cancer
type diabetes
randomized controlled trial
epidermal growth factor receptor
study protocol
tyrosine kinase
metabolic syndrome
machine learning